SCHEMBL1839102

SCHEMBL1839102

Nc1cc(-c2n[nH]c3ncnc(N4CCNCC4)c23)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
HTR2C P28335 5/20 0.42
BMPR1B O00238 1/20 0.41
BMPR1A P36894 1/20 0.41
ACVRL1 P37023 1/20 0.41
ACVR1 Q04771 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 2/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
LRRK2 Q5S007 2/20 0.39
ROCK1 Q13464 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1841531 0.72 LRRK2 (0.43) PIM1MKNK1MKNK2CLK4LRRK2
SCHEMBL1838247 0.72 LRRK2 (0.51) PIM1LRRK2DYRK1A
SCHEMBL28474570 0.72 HTR2C (0.49) HTR2CCYP1A2CYP3A4CYP2D6USP2
SCHEMBL1592892 0.71 PIM1 (0.45) PIM1PIM3PIM2BMPR1BBMPR1A
SCHEMBL30295802 0.69 LRRK2 (0.67) LRRK2
SCHEMBL13826604 0.68 LRRK2 (0.47) CYP1A2CYP3A4CLK4LRRK2LMNA
Hydrochloric Acid SCHEMBL2798625 0.68 HTR2C (0.45) PIM1HTR2CLRRK2ROCK1CDC42BPA
SCHEMBL1838682 0.68 LRRK2 (0.43) PIM1MKNK1MKNK2ALDH1A1CLK4
SCHEMBL1792053 0.67 RPS6KB1 (0.61) ALDH1A1LMNA
SCHEMBL6643085 0.66 ADRB2 (0.56) PIM1PIM3PIM2HTR2CBMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN disclosed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 PIM1 815/4885PIM3 961/4885PIM2 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.